Linked Life Data

12606512

Source:http://linkedlifedata.com/resource/pubmed/id/12606512

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12606512rdf:typepubmed:Citationlld:pubmed
pubmed-article:12606512lifeskim:mentionsumls-concept:C0017296lld:lifeskim
pubmed-article:12606512lifeskim:mentionsumls-concept:C0085243lld:lifeskim
pubmed-article:12606512lifeskim:mentionsumls-concept:C1705004lld:lifeskim
pubmed-article:12606512lifeskim:mentionsumls-concept:C0079646lld:lifeskim
pubmed-article:12606512lifeskim:mentionsumls-concept:C0011847lld:lifeskim
pubmed-article:12606512lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:12606512lifeskim:mentionsumls-concept:C2348628lld:lifeskim
pubmed-article:12606512pubmed:issue3lld:pubmed
pubmed-article:12606512pubmed:dateCreated2003-2-27lld:pubmed
pubmed-article:12606512pubmed:abstractTextIslet transplantation represents a potential cure for type 1 diabetes, yet persistent autoimmune and allogeneic immunities currently limit its clinical efficacy. For alleviating the autoimmune destruction of transplanted islets, newly diagnosed NOD mice were provided a single intramuscular injection of recombinant adeno-associated viral vector encoding murine IL-10 (rAAV-IL-10) 4 weeks before renal capsule delivery of 650 syngeneic islets. A dose-dependent protection of islet grafts was observed. Sixty percent (3 of 5) of NOD mice that received a transduction of a high-dose (4 x 10(9) infectious units) rAAV-IL-10 remained normoglycemic for at least 117 days, whereas diabetes recurred within 17 days in mice that received a low-dose rAAV-IL-10 (4 x 10(8) infectious units; 5 of 5) as well as in all of the control mice (5 of 5 untreated and 4 of 4 rAAV-green fluorescent protein-transduced). Serum IL-10 levels positively correlated with prolonged graft survival and were negatively associated with the intensity of autoimmunity. The mechanism of rAAV-IL-10 protection involved a reduction of lymphocytic infiltration as well as induction of antioxidant enzymes manganese superoxide dismutase and heme oxygenase 1 in islet grafts. These studies support the utility of immunoregulatory cytokine gene therapy delivered by rAAV for preventing autoimmune disease recurrence in transplant-based therapies for type 1 diabetes.lld:pubmed
pubmed-article:12606512pubmed:languageenglld:pubmed
pubmed-article:12606512pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12606512pubmed:citationSubsetAIMlld:pubmed
pubmed-article:12606512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12606512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12606512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12606512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12606512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12606512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12606512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12606512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12606512pubmed:statusMEDLINElld:pubmed
pubmed-article:12606512pubmed:monthMarlld:pubmed
pubmed-article:12606512pubmed:issn0012-1797lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:AgarwalAnupam...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:PileggiAntone...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:MolanoR...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:InverardiLuca...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:RicordiCamill...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:NickHarryHlld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:Campbell-Thom...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:CrawfordJames...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:PoggioliRaffa...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:Scott-Jorgens...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:ZhangY...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:PowersMatthew...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:WasserfallCli...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:FlotteTerence...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:EllisTamir...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:AtkinsonMark...lld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:BruskoToddTlld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:GoudyKevinKlld:pubmed
pubmed-article:12606512pubmed:authorpubmed-author:ZahrElsieElld:pubmed
pubmed-article:12606512pubmed:issnTypePrintlld:pubmed
pubmed-article:12606512pubmed:volume52lld:pubmed
pubmed-article:12606512pubmed:ownerNLMlld:pubmed
pubmed-article:12606512pubmed:authorsCompleteYlld:pubmed
pubmed-article:12606512pubmed:pagination708-16lld:pubmed
pubmed-article:12606512pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:meshHeadingpubmed-meshheading:12606512...lld:pubmed
pubmed-article:12606512pubmed:year2003lld:pubmed
pubmed-article:12606512pubmed:articleTitleAdeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice.lld:pubmed
pubmed-article:12606512pubmed:affiliationDepartment of Pathology, University of Florida, 1600 SW Archer Road, Gainesville, FL 32610-0275, USA.lld:pubmed
pubmed-article:12606512pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12606512pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:12606512pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12606512lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12606512lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12606512lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12606512lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12606512lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12606512lld:pubmed